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One-Day FISH Approach for the High-Speed
Determination of HER2 Gene Copy Status
in Breast Carcinoma
Katalin Hegyi,* Charlotte Lønborg,w Aniko´ Mo´nus,* and Ga´bor Me´hes, MD, PhD*
Abstract: Fluorescence in situ hybridization (FISH) is a com-
monly used method to detect chromosomal aberrations, for
example, to assess human epidermal growth factor receptor 2
(HER2) gene status in breast carcinoma. The classical FISH
approach requires overnight incubation for proper hybrid-
ization result. Tissue morphologic features are varying because
of aggressive pretreatment and application of high temperatures.
To eliminate some of the methodological problems, a new 1-day
FISH method was recently introduced. The aim of our study
was to evaluate the utility of the Instant Quality FISH with the
conventional FISH kit from the same provider (Dako
pharmDx) for determination of HER2 status.
We performed in situ hybridization on the same 40 invasive
breast carcinoma samples with both probe kits, and HER2/
CEN17 and chromosome 17/cell nucleus ratios were calculated.
FISH signal stability was also tested by the reassessment of the
slides after 2 months storage. The accordance regarding HER2
gene amplification status between the 2 FISH kits tested was
100%. There was an excellent correlation between HER2/
CEN17 ratios with a concordance correlation coefficient of
0.958 and correlation coefficient (R) of 0.959. The 1-day HER2
Instant Quality FISH diagnostic kit points with fast and stable
reaction showing the same result in the diagnostic practice when
compared with the conventional overnight FISH method.
Key Words: HER2, IQFISH, FISH, breast cancer, high-speed
FISH
(Appl Immunohistochem Mol Morphol 2013;00:000–000)
The human epidermal growth factor receptor 2 (HER2,c-erbB-2) gene localizes at 17q21 and encodes a
transmembrane tyrosine kinase receptor protein that is
involved in the process of cell growth.1
Amplification of HER2 geneAQ4 occurs in 15% to 25%
of invasive breast cancers.2 The gene amplification is as-
sociated with overexpression of the HER2 protein, a fea-
ture with strong prognostic impact for increased risk of
recurrence and short survival.3 As the HER2 status predicts
therapeutic response to cyclosporamide, methotrexate flu-
orouracil,4 and trastuzumab5,6 as well, the accurate deter-
mination of the gene status has great clinical significance.
In situ hybridization is a powerful molecular genetic
technique allowing the assessment of gene copy numbers by
microscopic visualization in interphase nuclei in form-
aldehyde-fixed and paraffin-embedded sections and tissue
microarray samples.7 Fluorescence in situ hybridization
(FISH) is a commonly used method for determining HER2
gene amplification status in breast cancer.8 Unfortunately,
the conventional FISH method performed on histologic
specimens is rather time consuming as an overnight in-
cubation is required for proper probe annealing and target
DNA hybridization.9 Moreover, tissue integrity is some-
times influenced by aggressive pretreatment and hybrid-
ization reagents. To overcome these problems, a modified
FISH method was recently introduced, which requires only
1.5 to 2 hours of hybridization time; thanks to the adjust-
ment of the hybridization buffer allowing also for the re-
duction of the denaturation temperature. The aim of our
study was to evaluate the performance of the new 1-day
FISH approach (HER2 IQFISH pharmDx, Glostrup,
Dako) and compare the data with those obtained by the
conventional overnight HER2 FISH setting supplied by the
same manufacturer.
MATERIALS AND METHODS
Patients and Samples
A total of 40 cases diagnosed with invasive breast
carcinoma at the Department of Pathology, University of
Debrecen, were prospectively selected. Routine form-
aldehyde-fixed and paraffin-embedded specimens con-
sisted of surgically resected carcinomas and tumor
biopsies. The sample set contained 38 invasive ductal and
2 invasive lobular carcinomas (Table 1). All evaluated
carcinomas showed scores of 2 or 3 HER2 positivity by
immunohistochemistry.
FISH Procedure
In situ hybridization was performed on 5 mm thick
sections with both HER2 FISH pharmDx (Dako) and
HER2 IQFISH pharmDx (Dako) probe kits on serial
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sections according to the manufacturer’s protocol. The
main differences in the 2 protocols are shown in Figure 1.
Deparaffinized sections (NeoClear, Merck, Darm-
stadt) were pretreated with MES [2-(N-morpholino)
ethanesulfonic acid, provided by the 2 kits] buffer fol-
lowed by proteolytic digestion using pepsin (provided by
the kits). Ready-to-use pepsin solution was dropped on
slides for performing conventional FISH, and diluted
pepsin solution was applied in cuvette for Instant Quality
FISH (IQFISH). After washing in 1 wash buffer (pro-
vided by the kits), slides were dehydrated through a
graded series of ethanol and the ready-to-use probe mix
was applied to the sections, coverslipped, and sealed.
Denaturation and hybridization were performed in
a hybridization chamber (StatSpin ThermoBrite, Abbott
Molecular). Slides were denatured at 821C for 5 minutes
for conventional HER2 pharmDx, and at 661C for
10 minutes for the IQFISH probe. Hybridization was
performed overnight for the conventional HER2 FISH
and 90 minutes for HER2 IQFISH protocol at 451C in
both options. Stringent wash was performed at 651C for
conventional FISH and at 631C for IQFISH for 10 mi-
nutes for both kits. Slides were dehydrated and covered
with DAPI containing antifade solution and coverglass.
Storage was at 41C in the dark until evaluation.
Evaluation of FISH Results
Signals were counted using Zeiss Axio Imager Z2
fluorescence microscope equipped with DAPI, FITC, and
Texas Red filters in a blind fashion. Fluorescence images
were archived with the Isis imaging system (MetaSystems,
Altlussheim, Germany).
Microscopic evaluation was carried out on the basis
of the current guidelines,10 including the overview of the
whole hybridization area to determine relevant tumor-
containing areas and to exclude heterogeneity. After the
general assessment of the HER2 status, chromosome 17
(green) and HER2 (red) FISH signals were counted in 20
nuclei in representative areas using a 63 immersion oil
objective for all samples and HER2/CEN17 ratios were
calculated. Samples with ratio above 2.2 were considered
HER2 amplified, ratios between 1.8 and 2.2 were con-
sidered as borderline, whereas ratios below 1.8 as non-
amplified. If the HER2/CEN17 ratio was in the
borderline range, additional 20 nuclei were counted and
ratios were recalculated. Chromosome 17 copy numbers
were considered as normal between 1.5 and 2.3 CEN17
signals per nucleus, partial monosomy was stated
below 1.5, and polysomy was stated above 2.3 signals per
nucleus.
Reassessment of the same slides after 2 months
storage at 41C was performed to obtain information on
FISH signal stability. The reassessment was carried out
according to the same technique as described for the first
evaluation.
Statistical Analysis
Comparative study of Dako HER2 FISH and
IQFISH pharmDx was performed determining the con-
cordance correlation coefficient and confidence interval.
MedCalc and SPSS statistical softwares were used for
analysis.
RESULTS
All 40 breast carcinoma samples gave appropriate
results for both the conventional HER2 FISH and for the
new HER2 IQFISH. The accordance between the results
by the 2 kits regarding HER2 gene amplification status
was 100%. Seventeen of the 40 cases were stated as HER2
nonamplified and showed chromosome 17 disomy, 3/40
were stated as HER2 nonamplified with chromosome 17
polysomy, 16/40 cases were HER2 amplified with chro-
mosome 17 disomy, and 4/40 cases proved to be HER2
amplified with chromosome 17 polysomy. The correlation
between HER2/CEN17 ratios were found to be high, with
a concordance correlation coefficient of 0.958 and a cor-
relation coefficient (R) of 0.959 (Fig. 2).
In 3 cases the result of in situ hybridization using
the conventional HER2 FISH kit was difficult to interpret
because of poor cellular morphology and/or background
fluorescence. The extended evaluation of additional areas
was necessary and the signal ratios had to be recalculated
to determine amplification status. In all these 3 cases, a
clear tissue architecture and fluorescence signals and less
autofluorescence was seen using HER2 IQFISH kit. Ac-
cordingly, unambiguous FISH result was obtained after
the standard evaluation of the 20 tumor cell nuclei
(Fig. 3).
The reevaluation of the same FISH slides after
2 months storage at 41C following the original study was
carried out to check fluorescence stability and reprodu-
cibility of the reaction obtained by the new FISH kit.
In this blinded analysis, we could not find significant
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TABLE 1. Histopathologic Characteristics of the Breast
Carcinoma Samples Evaluated for Conventional HER2 and
1-Day IQFISH (n=40)
Variables No. Cases
Histotype
Ductal 38
Lobular 2
ER status
Negative 4
Positive 35
Unknown 1
PR status
Negative 8
Positive 32
c-erb-B2 score
– 0
+ 0
++ 25
+++ 15
HER2 amplification
Negative 20
Positive 20
ER indicates estrogen receptor; HER2, human epidermal growth factor re-
ceptor 2; IQFISH, Instant Quality fluorescence in situ hybridization; PR, pro-
gesterone receptor.
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differences in the final interpretation (Table 2). Tissue
morphology was well preserved after 2 months storage;
however, 2 slides (2/40, 5%) from the conventional FISH
series were no longer appropriate for microscopic evalu-
ation because of almost complete disappearance of the
signals. In general, the fading of the HER2 and the cen-
tromere 17 signals could be seen in both FISH ap-
proaches during reevaluation. Interestingly, mean HER2
signal copy/nucleus dropped only by 0.95 copy/nucleus
when IQFISH was used in contrast with 1.82 copy/nucleus
difference following the conventional FISH method
(Fig. 4). Even more fading could be stated for the chro-
mosome 17 signals that was dominant in the slides ap-
proached by the conventional FISH method (0.01 copy/
nucleus loss for IQFISH when compared with 0.17 copy/
nucleus loss for the conventional assay) (Fig. 4). After
reassessment, a different HER2 gene amplification status
was stated in 5 cases for both kits; all 5 cases originally
stated as HER2 low-grade amplified shifted over to the no
amplification group after reassessment. In 1 additional
case, only low-grade amplification was observed after
reevaluation in an originally highly amplified sample after
the use of the conventional HER2 FISH kit.
DISCUSSION
In situ hybridization is the gold standard used in the
everyday practice for the determination of the HER2
status in breast carcinoma.11 The conventional FISH
technique on histology samples requires 2 days because of
overnight hybridization of the probes. The new IQFISH
method was developed to shorten the procedure and
allow a 1-day application requiring only 1.5 to 2 hours
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Apply DAPI
Coverslip
Read
HER2 FISH pharmDx™ HER2 IQFISH pharmDx™
Pre-Treatment Solution 95-99°C 10 min (MWO)
Cool at RT 15 min
Wash Buffer 2x3 min
Pepsin Solution (diluted, in cuvette)
Solution 37°C 20 min
Wash buffer 2x3 min
Denaturation 66°C 10 min
Hybridization 45°C 90 min
(ethylene carbonate instead of formamide)
NeoClear 2x5 min
Graded ethanol series
Wash Buffer 2 min
Remove coverslip
Stringent wash 65°C 10 min
Wash buffer 3 min
Deparaffinization
Pretreatment
Pepsin
digestion
Codenaturation,
hybridization
Stringent wash
Mounting
NeoClear 2x5 min
Graded ethanol series
Wash Buffer 2 min
Pepsin RTU 5-8 drops
Incubate at RT 5 min
Denaturation 82°C 5 min
Hybridization 45°C
overnight
Remove coverslip
Stringent wash 65°C 10 min
Wash buffer 3 min
Apply DAPI
Coverslip
Read
Pre-Treatment Solution 95-99°C 10 min (MWO)
Cool at RT 15 min
Wash Buffer 2x3 min
FIGURE 1. Main differences in the reaction protocols between the conventional HER2 FISH and the new 1-day IQFISH compared
in this study. FISH indicates fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IQFISH, Instant
Quality FISH.
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FIGURE 2. Correlation between the HER2/CEN17 relative
copy number ratios determined by the 2 FISH kits. Strong
correlation was found with concordance correlation coefficient
0.958 and correlation coefficient (R) 0.959. FISH indicates
fluorescence in situ hybridization; HER2, human epidermal
growth factor receptor 2.
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for proper probe binding. The modification in the hy-
bridization chemistry resulted in 2 major qualitative
changes: both (1) reduced temperature (only 661C)
heat denaturation, and (2) short hybridization time (only
1.5 h) significantly improve sample handling and tissue
morphology.
We found a 100% accordance regarding HER2
amplification and chromosome 17 copy number between
the new 1-day FISH and the conventional FISH tests
indicating the absence of bias between the 2 methods. The
correlation between the HER2/CEN17 ratios was very
good. Reaction interpretation problems were virtually
absent in case of the 1-day approach in the evaluated
series of cases but a high fluorescence background inter-
fered with the FISH signal in 3 samples resulting in am-
biguous values by the conventional HER2 pharmDX kit.
Such technical issues are repeatedly observed in routine
FISH diagnostics and are usually associated with sub-
optimal fixation and tissue handling. These cases could be
cleared after exhaustive counting of additional 20 tumor
cell nuclei and recalculation of the ratios as described.
Two of these cases were found to be HER2 nonamplified
with chromosome 17 disomy and 1 case was found to be
HER2 amplified with chromosome 17 disomy. In con-
trast, the use of the IQFISH approach eliminated most of
the autofluorescence and tissue damage was also much
less obvious in any of the slides. These observations led us
to conclude that the modified hybridization conditions
favor tissue morphology and avoid the generation of
autofluorescence when IQFISH was used.
Reassessment of the slides provided us with further
data regarding the stability of the FISH signals during
long-term storage. IQFISH performed clearly better in
the signal intensity and reproducibility after 2 months
storage. Although this feature seems to have relatively
little value in the current setting, stability of fluorescence
preparations, for example, for quality assurance pur-
poses, is a recurrent problem and is a major argument for
chromogenic FISH applications. A long-term effect of
storage on IQFISH signals was not tested in the frame of
our study but an improved preservation of FISH signals
over a 2-month period was well stated. As an interesting
observation in our setting, both the red (HER2) and the
green (centromere 17) signal intensities were significantly
reduced when conventional FISH approach was used.
This resulted in different interpretation of the relative
HER2 copy number in selected cases primarily having an
impact on quality assurance approaches in the future. In
this context, it is of special interest that FISH signal
reading proved to be much easier after reevaluation be-
cause of enhanced fluorescence stability when IQFISH
was used.
In summary, the 1-day HER2 IQFISH approach is
a potent method for the determination of HER2 status
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FIGURE 3. FISH images illustrating differences between con-
ventional HER2 FISH (A1, B1, C1) and IQFISH (A2, B2, C2) of
the same breast carcinoma tissue material. High fluorescence
background was detected in these samples by the conven-
tional method (left column), whereas clear signals and good
morphology was obtained after IQFISH (right column). FISH
indicates fluorescence in situ hybridization; HER2, human ep-
idermal growth factor receptor 2; IQFISH, Instant Quality FISH.
TABLE 2. Relative Copy Numbers per Cell Nucleus of HER2 and Chromosome 17 Signals Evaluated Within 24 Hours After the
FISH Reaction (First Assessment) and After 2 Months Storage of the FISH Preparations at 41C (Second Assessment)
HER2/Nucleus (Mean±SD, n=40) Chromosome 17/Nucleus (Mean±SD, n=40)
First Assessment Second Assessment P First Assessment Second Assessment P
Conventional HER2 FISH 7.14±8.04 5.32±6.11 0.27 1.97±0.40 1.8±0.64 0.18
IQFISH 6.85±7.64 5.9±6.64 0.56 1.99±0.44 1.98±0.51 0.92
FISH indicates fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IQFISH, Instant Quality FISH.
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offering some relevant advances further to the short in-
cubation time, including enhanced tissue integrity and
preserved fluorescent signal intensity when compared
with the conventional HER2 FISH kit. All these features
make fluorescence detection more competitive in the
area of light microscopy-based in situ hybridization
approaches.
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FIGURE 4. Relative mean copy numbers of HER2 and chromosome 17 signals per cell nucleus in 40 breast carcinoma samples
calculated after the initial evaluation and a reassessment after 2 months storage (41C) of the slides. At the first assessment, the
mean HER2/nucleus ratio was found to be 7.14 ±8.04 by conventional HER2 kit and 6.85 ±7.64 by IQFISH; these values were
observed as 5.32 ±6.11and 5.9 ± 6.64 after reevaluation. Relative chromosome 17 mean copy number were 1.97 ±0.40 using
conventional kit and 1.99 ±0.44 using IQFISH kit; these values were found as 1.8 ± 0.64 and 1.98 ±0.51 after 2 months storage.
HER2 indicates human epidermal growth factor receptor 2; IQFISH, Instant Quality fluorescence in situ hybridization.
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